Turner Financial Group Inc. Invests $582,000 in Tempus AI, Inc. $TEM

Turner Financial Group Inc. acquired a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the second quarter, HoldingsChannel.com reports. The firm acquired 10,043 shares of the company’s stock, valued at approximately $582,000.

Several other large investors also recently modified their holdings of TEM. Odyssean LLC acquired a new stake in shares of Tempus AI during the 2nd quarter worth about $897,000. Nykredit A S bought a new position in shares of Tempus AI during the second quarter worth approximately $186,000. EMC Capital Management acquired a new stake in Tempus AI during the 2nd quarter worth approximately $29,000. Legacy Financial Advisors Inc. bought a new stake in Tempus AI in the 2nd quarter valued at $235,000. Finally, Headlands Technologies LLC acquired a new position in Tempus AI in the 2nd quarter valued at $2,689,000. 24.22% of the stock is owned by institutional investors.

Insider Transactions at Tempus AI

In other news, EVP Andrew Polovin sold 22,148 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the sale, the executive vice president directly owned 146,067 shares in the company, valued at approximately $7,246,383.87. The trade was a 13.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the transaction, the chief executive officer directly owned 200,000 shares of the company’s stock, valued at $8,412,000. This represents a 55.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,043,988 shares of company stock worth $56,963,417 in the last 90 days. 24.26% of the stock is currently owned by company insiders.

Tempus AI Stock Down 0.1%

TEM stock opened at $64.62 on Friday. The stock has a market capitalization of $11.66 billion, a P/E ratio of -44.87 and a beta of 3.72. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a 50-day moving average price of $55.77 and a 200-day moving average price of $52.13. Tempus AI, Inc. has a 12 month low of $40.77 and a 12 month high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter last year, the business posted ($0.22) earnings per share. The company’s quarterly revenue was up 21.6% on a year-over-year basis. As a group, equities research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TEM shares. Cantor Fitzgerald assumed coverage on shares of Tempus AI in a research report on Wednesday. They issued an “overweight” rating and a $80.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Freedom Capital raised shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Finally, Weiss Ratings cut shares of Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. Eleven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $68.93.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.